CX3CL1 (C-X3-C motif chemokine ligand 1), commonly known as fractalkine, is a uniquely structured chemokine that serves as the primary molecular link between neurons and microglia in the central nervous system[1][2]. Unlike conventional chemokines that function as soluble chemoattractants, CX3CL1 exists in two distinct forms: a membrane-bound molecule that mediates direct cell-cell adhesion, and a soluble proteolytic fragment that acts as a classical chemokine. This dual functionality positions CX3CL1 at the nexus of neuroimmune communication, controlling microglial activation states, synaptic function, and neuronal survival under both physiological and pathological conditions.
CX3CL1 signals exclusively through its receptor CX3CR1, which is expressed predominantly on microglia in the brain, creating a dedicated neuron-to-microglia communication axis[3]. This receptor-ligand pair has emerged as a critical modulator of neuroinflammatory processes and synaptic dysfunction in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
| Property | Value |
|---|---|
| Gene Symbol | CX3CL1 |
| Full Name | C-X3-C Motif Chemokine Ligand 1 |
| Aliases | Fractalkine, NTN, ABCD-3 |
| Chromosomal Location | 16q13 |
| NCBI Gene ID | 6376 |
| OMIM | 601880 |
| Ensembl ID | ENSG00000175782 |
| UniProt ID | P45473 |
CX3CL1 is a type I transmembrane protein with a distinctive structure[1:1]:
CX3CL1 exists in two functionally distinct forms[3:1][4]:
| Form | Generation | Primary Function |
|---|---|---|
| Membrane-bound | Direct translation, no cleavage | Adhesion molecule; allows firm attachment of microglia to neurons |
| Soluble (sCX3CL1) | Proteolytic shedding by ADAM10/ADAM17 | Classical chemokine; attracts microglia, modulates synaptic function |
ADAM10 generates the constitutively soluble form under normal conditions, while ADAM17 (induced by inflammatory stimuli) produces a more rapidly shed soluble fragment that amplifies the chemotactic signal during neuroinflammation.
CX3CL1/CX3CR1 signaling represents the principal neuron-to-microglia communication pathway in the healthy brain[2:1][3:2]:
During development and adulthood, CX3CL1/CX3CR1 regulates synaptic remodeling[5][6]:
CX3CL1 provides a brake on microglial activation under physiological conditions[3:3]:
CX3CL1/CX3CR1 provides direct neuroprotective signals[7][8]:
CX3CL1 is dysregulated in Alzheimer's disease, with changes detectable in patient samples[9][10]:
CX3CL1/CX3CR1 signaling modulates core AD pathological features[7:1][@tritch2007]:
CX3CL1 regulates synaptic integrity in AD models[5:1]:
Restoring CX3CL1/CX3CR1 signaling represents a therapeutic strategy in AD[12][7:2]:
| Approach | Mechanism | Evidence |
|---|---|---|
| Recombinant sCX3CL1 | Direct neuroprotection, microglial modulation | Reduces Aβ toxicity in vitro; improves cognition in APP/PS1 mice |
| CX3CR1 agonists | Enhance neuroprotective signaling | Synthetic agonists show promise in mouse models |
| Gene therapy | Increase neuronal CX3CL1 expression | AAV-mediated CX3CL1 delivery reduces neuroinflammation |
CX3CL1/CX3CR1 signaling is altered in Parkinson's disease, contributing to dopaminergic neuron vulnerability[13]:
CX3CL1 modulates alpha-synuclein pathology and associated neuroinflammation:
CX3CL1/CX3CR1 is implicated in ALS pathophysiology[14]:
CX3CL1/CX3CR1 signaling modulates pain pathways[15]:
CX3CR1 engages multiple downstream signaling cascades upon CX3CL1 binding:
CX3CL1 → CX3CR1 (GPCR, Gi/o-coupled)
├── Gi/o-mediated signaling
│ ├── AKT/PKB activation → pro-survival
│ ├── ERK1/2 activation → gene expression, neuroprotection
│ └── PI3K activation → cytoskeletal dynamics
└── G-protein independent pathways → anti-inflammatory tone
CX3CR1 signaling modulates TLR and NLRP3 inflammasome pathways[3:4][6:1]:
| Model | Observations | Key Findings |
|---|---|---|
| CX3CR1 knockout mice | Viable, altered microglia | Hyper-ramified microglia, enhanced inflammatory responses |
| CX3CL1 knockout mice | Similar to CX3CR1 KO | Synaptic pruning deficits, behavior changes |
| 5xFAD/CX3CR1-KO | AD model on KO background | Accelerated amyloid pathology, synaptic loss |
| MPTP/CX3CR1-KO | PD model on KO background | Enhanced dopaminergic neuron loss |
| SOD1/CX3CL1-Tg | ALS model with CX3CL1 overexpression | Improved motor neuron survival |
Developing CX3CR1 agonists to replace lost CX3CL1 signaling:
| Compound | Approach | Status |
|---|---|---|
| Synthetic CX3CL1 mimetics | Engineered CX3CL1 fragments | Preclinical |
| Small molecule CX3CR1 agonists | Non-peptide agonists | Early research |
| Antibody-based agonists | CX3CR1-activating antibodies | Research stage |
Recombinant protein and gene therapy strategies for CX3CL1 restoration[12:1][@rozendahl2021]:
CX3CL1 (fractalkine) is a uniquely bifunctional chemokine that serves as the primary molecular bridge between neurons and microglia. Its membrane-bound form enables direct cell-cell adhesion, while the soluble form provides classical chemokine signaling to attract and modulate microglial activity. The exclusive receptor (CX3CR1) on microglia creates a dedicated neuroimmune communication channel that regulates surveillance, synaptic pruning, and inflammatory tone under physiological conditions.
In Alzheimer's disease, CX3CL1 levels decline in CSF and brain tissue, contributing to excessive microglial activation, impaired Aβ clearance, and synaptic loss. In Parkinson's disease, loss of CX3CL1 from dopaminergic neurons renders them more vulnerable to inflammatory damage. Restoring CX3CL1/CX3CR1 signaling—through recombinant protein, small molecule agonists, or gene therapy—represents a promising therapeutic strategy to rebalance neuroinflammation and provide direct neuroprotection across neurodegenerative conditions.
Bazan JF, Xu W, Grivel JC, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997. ↩︎ ↩︎
Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proceedings of the National Academy of Sciences. 1998. ↩︎ ↩︎
Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nature Neuroscience. 2006. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Finneran DJ, Krishnan B, et al. CNS跨境 fractalkine signaling in neuroprotection. Cellular and Molecular Neurobiology. 2009. ↩︎
Leydig J, et al. CX3CR1 deficiency leads to enhanced synaptic pruning in Alzheimer's disease. Glia. 2018. ↩︎ ↩︎
Lyons A, et al. Microglial-derived CX3CL1 in the aged brain. Aging Cell. 2017. ↩︎ ↩︎
Morganti JM, Nash KR, Grimmig BA, et al. The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Alzheimer's disease. Neurobiology of Aging. 2012. ↩︎ ↩︎ ↩︎
Lauranzano E, et al. Human iPSC-derived neurons reveal CX3CL1-mediated neuroprotection. Stem Cell Reports. 2015. ↩︎
Kim TS, Lim GJ, Cho MY, et al. Decreased CX3CL1 levels in the cerebrospinal fluid of patients with Alzheimer's disease. Neuroscience Letters. 2008. ↩︎
Pavelek Z, et al. Soluble CX3CL1 levels in CSF and serum in Alzheimer's disease and controls. Journal of Neurological Sciences. 2019. ↩︎
McMullan H, Vivekanandan S, Stankovich J, et al. CX3CR1 variant is associated with Alzheimer's disease risk. Neurobiology of Aging. 2013. ↩︎
Mecca C, et al. Fractalkine-based therapeutics in neurodegenerative disease models. Neuropharmacology. 2022. ↩︎ ↩︎
Leonardi B, Adams M, et al. CX3CL1/CX3CR1 signaling in Parkinson's disease models. Journal of Neuroscience Research. 2012. ↩︎
Subbarayan MS, et al. CX3CL1 in ALS: microglial activation and motor neuron vulnerability. Acta Neuropathologica. 2012. ↩︎
Sheridan GK, Murphy K, et al. Fractalkine and CX3CR1 in pain processing and neuroinflammation. Pain. 2014. ↩︎